ClinicalTrials.gg
Not yet recruitingNCT06683131IMPROVE-AMIUpdated Nov 21, 2025

Effectiveness of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor Initiation Before Percutaneous Coronary Intervention on Acute Myocardial Infarction Patients

A Phase 4 interventional study of Tafolecimab in Acute Myocardial Infarction (AMI), sponsored by The Affiliated Hospital of Xuzhou Medical University. Not yet recruiting at 13 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-11-21.

Sponsored by The Affiliated Hospital of Xuzhou Medical University · Phase 4, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
1,160
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 196 studies in Myocardial Infarction with a site in China — 64 open to participants now, 73 under way, 8 of them phase 3. Myocardial Infarction · China.

Planned enrollment
33rd of 107
1,160 · median 366
Started
2025
with 19 others
Phase 4
32 of 196
8 open now
Primary completion
2027-11
later than 47 of 72 live
Registered
140th of 196
by date

Among the 196 studies in Myocardial Infarction with a site in China, this one is the 33rd largest by planned enrollment of the 107 interventional ones that give a count, is one of 20 that started in 2025, is one of 32 in phase 4, reaches primary completion later than 47 of the 72 other live ones, and was the 140th registered.

Myocardial Infarction

2,273 studies on the registry are indexed under Myocardial Infarction; 373 are open to participants now.

Browse Myocardial Infarction studies →

Open to participants now

64 of the 196 studies in Myocardial Infarction with a site in China are open now. Recruiting first, the newest first:

59 more — sign in →

All 64 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 256 Myocardial Infarction studies recruiting now, 173 (68%) set no upper age limit and 25 (10%) stop at 75 or younger; 17 take children under 18; 27 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 196 studies in Myocardial Infarction with a site in China, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn if drug tafolecimab works to treat participants with acute myocardial infarction (AMI) scheduled for primary percutaneous coronary intervention (PCI). It will also learn about the safety of drug tafolecimab. The main questions it aims to answer are:

  • Does drug tafolecimab lower the risk of 1-year major adverse cardiovascular events?
  • Does drug tafolecimab improve the coronary microvascular dysfunction?
  • What medical problems do participants have when administering drug tafolecimab by injection? Researchers will compare the results administering drug tafolecimab or not to see if drug tafolecimab works to treat AMI.

Participants will:

  • Administer drug tafolecimab by injection or not every month for 12 months
  • Receive the standard of care of AMI
  • Complete the measurement of coronary angiography-derived microcirculation resistance index after PCI
  • Complete cardiac magnetic resonance after PCI if available
  • Visit the clinic at 1,6,12 months after the first administration for checkups and tests
  • Report any discomfort, event or queries at any time
03

Conditions studied

  • Acute Myocardial Infarction (AMI)

Keywords

  • Acute Myocardial Infarction
  • tafolecimab
  • PCSK9
  • Coronary Microvascular Dysfunction
  • Major adverse cardiovascular events
  • monoclonal antibody against proprotein convertase subtilisin/kexin type 9
  • LDL-C
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults 18-75 years old
  • AMI diagnosed according to the latest guidelines, including ST-segment elevation myocardial infarction (STEMI) and non-ST-segment elevation myocardial infarction (NSTEMI)

    • The requirement for STEMI was that primary PCI was scheduled within 12 hours of onset.
    • The requirement for NSTEMI was that coronary angiography was scheduled within 2 hours for very high-risk participants and within 24 hours for high-risk participants .
  • Regardless of baseline LDL-C levels
  • Participants voluntarily took part in this study and signed

Exclusion criteria

Exclusion Criteria:

  • Previous or ongoing treatment for any PCSK9i
  • Allergy to PCSK9i, statins, or any of the drug ingredients used during the trial
  • History of hemorrhagic cerebrovascular disease
  • History of old myocardial infarction/chronic heart failure
  • History of PCI or coronary artery bypass grafting (CABG) or preparation for CABG
  • Above Killip level II
  • Prolonged cardiopulmonary resuscitation (>20min)
  • Definite mechanical complications (including perforation of the interventricular septum, or rupture of the papillary tendon bundle or the left ventricular free wall)
  • malignant arrhythmia
  • Severe uncontrolled infection, bleeding disorder, end-stage renal disease, severe liver disease, endocrine dysfunction, or the expected less than 1 year survival of malignant tumors
  • Pregnant or lactating women
  • Participate in other clinical trials
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,160 participants (estimated)

Study arms

  • Experimental
    PCSK9 inhibitor (PCSK9i) group

    Participants receive PCSK9i tafolecimab and standard of care (SoC) of acute myocardial infarction

    Drug: Tafolecimab

  • No intervention
    Control group

    Participants receive SoC of acute myocardial infarction

Interventions

  • 450mg of tafolecimab (150mg each one) was injected subcutaneously before primary PCI and then 150mg subcutaneously injected every half a month till totally 12 months.

06

What researchers measure

Primary outcomes

  1. Rate of major adverse cardiovascular events (MACEs)

    MACEs including cardiovascular death, nonfatal myocardial infarction, unplanned ischemia-driven revascularization, nonfatal stroke, hospitalization for heart failure

    Time frame: From enrollment to 1 year after primary percutaneous coronary intervention

Secondary outcomes

  1. Number of participants with coronary microvascular dysfunction (CMD)

    Measurement of coronary angiography-derived microcirculation resistance index (caIMR)

    Time frame: Immediately after primary percutaneous coronary intervention

  2. Number of participants with coronary microvascular dysfunction (CMD)

    Infarct size (IS), intramyocardial hemorrhage (IMH) and microvascular obstruction (MVO) assessed by cardiac magnetic resonance

    Time frame: 3-7 days after primary percutaneous coronary intervention

  3. Concentration of low density lipoprotein cholesterol (LDL-C)

    The measurement of LDL-C level and number of participants reaching the target according to current guidelines

    Time frame: Both 1 month and 1 year after primary percutaneous coronary intervention

  4. Rate of malignant arrhythmia

    These include sudden cardiac death (SCD), sudden death survival (aborted SCD), appropriate implantable cardioverter defibrillator (ICD) interventions, and persistent ventricular arrhythmias monitored by a 72-hour holter electrocardiogram.

    Time frame: 1 month after primary percutaneous coronary intervention

07

Study locations

13 sites
08

References and documents

Individual participant data

Plan to share: No — Participants do not consent to the data sharing about themselves. IPD involves privacy and ethical issues.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2025; primary completion for Nov 2027, 24 months later.

Of 83 non-industry phase 4 interventional studies under Myocardial Infarction, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 78. This study's planned 24 months is below that.

Counting every sponsor, half of 87 studies reached it within 42 months; a quarter within 22 and three quarters within 78.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 8, 2024
First posted
Nov 12, 2024
StartEst.
Nov 20, 2025
Primary completionEst.
Nov 30, 2027
CompletionEst.
Nov 30, 2027
Last update
Nov 21, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 21, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06683131
Lead sponsor
The Affiliated Hospital of Xuzhou Medical University
Responsible party
Sponsor
First posted
Nov 12, 2024
Start date
Nov 20, 2025 (estimated)
Primary completion
Nov 30, 2027 (estimated)
Completion
Nov 30, 2027 (estimated)
Last update
Nov 21, 2025

Study contacts

Yuan Lu, M.D. and Ph.D.
Contact
drluyuan329@163.com
+8613952110901
Yiwen Wang, M.D.
Contact
wangyiwen@xzhmu.edu.cn
+8615094343962
Yong Huo, M.D. and Ph.D.
study chair · Peking University First Hospital
Yuan Lu, M.D. and Ph.D.
principal investigator · The Affiliated Hospital of Xuzhou Medical University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tafolecimab

Start the discussion